IC-PTE 2024

Details

Date: May15^th - 18^th 2024

Location: Mario Negri Institute, Milan, Italy

Organization Committee

Elisa Zanier, MD
Maria Negri Institute
Co-Chair

Anna Vezzani, PhD
Mario Negri Institute

Alexandra Ulyanova, PhD
University of Pennsylvania

Laura Lubbers, PhD
CURE Epilepsy
Co-Chair

Teresa Ravizza, PhD
Mario Negri Institute

Federico Moro, PhD
Mario Negri Institute

Program 2024

May 15^th 2024

Opening Reception

Challenges in PTE Research: The Need for Biomarkers and Research Standards
Severn B. Churn, PhD, Program Director of Synapses, Channels and Neural Circuits NIH, USA

May 16^th 2024

Welcome and Opening Remarks

• Laura Lubbers, PhD, Chief Scientific Officer, CURE Epilepsy, USA
• Elisa Zanier, MD Head of Department, Mario Negri Institute for Pharmacological Research, Italy
• Giuseppe Remuzzi, MD, Director of Mario Negri Institute for Pharmacological Research, Italy

Post-Traumatic Epilepsy: The Lived Experience

• Jack Somers, Captain, United State Marine Corps, Retired
• Moment of Silence & Reflection

Clinical PTE: Recent Advances, Challenges and Solutions

Overview of PTE and Goals of the Conference
Ramon Diaz-Arrastia, MD, PhD, Director TBI Clinical Res. Center, University of Pennsylvania, USA

Mechanistic Targets for PTE Prevention
Wolfgang Löscher, PhD, Professor, Hanover Medical School, Germany

Advances in the Neuropathological Characterization of PTE following TBI
Victoria Johnson, MBChB, PhD, Assistant Professor, University of Pennsylvania, USA

Predicting PTE Risk: The Development of a Risk Tool for PTE
Amy Wagner, MD, Professor, University of Pittsburgh, USA

Synthesis of Concepts and Discussion of Next Steps

1. How will we select the first/best biological mechanisms to test in clinical trials?
2. What supporting data will be required?

Promising Clinical Biomarkers of PTE
Moderator David Brody, MD, PhD

Blood-Based Biomarkers of PTE
Kevin Wang, PhD

Immune-Based Biomarkers: Lessons from TBI
Edward Needham, MD, PhD

EEG Biomarkers: Lessons from Acquired Epilepsy in the ICU
Edilberto Amorim, MD

Innovations in Brain Imaging: Implications for Post-Traumatic Epilepsy
David Brody, MD, PhD

Blood-Borne Protein Biomarkers of Post-Traumatic Epilgenesis; Gaps and Solutions
Denes Agoston, MD, PhD

Synthesis of Concepts and Discsuion of Next Steps

1. What criteria must be met to establish that biomarkers are ready for use?
2. What level of characterization and sensitivity threshold is required?

PTE: The Industry Perspective on Needs for Clinical Trial
Moderator: Douglas H. Smith

Needs for Developing Biomarkers for PTE Clinical Trials
William Haskins, PhD, Gryphon Bio, USA

Challenges in the Oath to a Clinical Trial: The Startup Perspective
Pavel Klein, MD, Mid-Atlantic Epilepsy and Sleep Center

Synthesis of Concepts and Discussion of Next Steps

1. How do we foster collaboration between industry partners and researchers?
2. How do we ensure we address industry needs to move the field forward?

May 17^th 2024

Welcome and Day 1 Recap
Elisa Zanier, MD, Mario Negri Insitute, Italy

Partnering with Lived-Experience PTE Community
Melissa Miller, PhD, US Department of Defense

Preclinical PTE: Advances, Challenges and Solutions
Moderator: David Loane, PhD, Trinity College, Ireland

Neuroinflamation as a Mechanism of Epileptogenesis: Insights from Status Epilepticus Models
Annamaria Vezzani, PhD, Mario Negri, Italy

Determining the Validity of Preclinical Animal Models
Aristea Galanpoulou, MD, PhD, Albert Einstein College of Medicine, USA

Synthesis of Concepts and Discsuion of Next Steps

1. How will we select the first/best biological mechanisms to test in clinical trials?
2. What supporting data will be required?

Promising Preclinical Biomarkers of PTE
Moderator: Kevin Staley, MD, Harvard School of Medicine, USA

Multi-omic Biomarkers of PTE
Firas Kobaissy, PhD, Morehouse School of Medicine, USA

Imaging Biomarkers of PTE
Federico Moro, PhD, Mario Negri, Italy

Preclinical EEG Biomkarkers of PTE
Asla Pitkänen, MD, PhD, University of Easern Finalnad, Finland

Developing Treatments for PTE: The Translational View
Terence O'Brien, MD, Monash University, Australia

Synthesis of Concepts and Discussion of Next Steps

1. When are biomarkers ready for use?
2. What level of characterization and sensitivity threshold is required?

Hot Topics in PTE: Data Blitz Presentations
Moderator, Christopher Dulla, PhD, Tufts University, USA

Early Career Winners

• Ilaria Lisi, Mario Negri Institute, Italy
• Bin Gu, PhD, Ohio State University, USA
• Irma Ngadimon, PhD, Monash University, Malaysia

Oral Presentations

• Justin Weppner, MD, Virginia Tech Carilion School of Medicine, USA
• Tawfeeq Shekh-Ahmad, PhD, Hebrew University of Jerusalem, Israel

Discussion

May 18^th 2024

Welcome and Recap

Elisa Zanier, PhD, Maria Negri Institute, Italy

Involvement of Affected Individuals and the Public in PTE Clinical Research

Daniel Correa, MD, MS, Albert Einstein College of Medicine, USA

Developing the Data Infrastructure Needed for Progress in PTE
Moderator: Severn "Ben" Churn, NIH, USA

Federated Platforms/Systems for Validation and Optimization of Preclinical Findings
Joost Wagenaar, PhD, University of Pennsylvania, USA

Harnessing the Power of Big Data for PTE Analysis: Next Steps in Multi-Modal Data Analysis and Field-Wide Data Standardization
Dominique Duncan, University of Southern California, USA

Data Sharing and Standardization: Lessons from the Federal Inter-agency TBI Research (FITBIR) Informatics System
Hibah Awwad, PhD, NINDS/NIH, USA

Discussion

1. What considerations must be taken into account, from the researchers’ perspective, to ensure buy-in to federated data ecosystem? 
2. What additional resources or technology are needed to achieve multimodal analysis?

The Roadmap to an Interventional Trial of PTE

• Moderators: Laura Lubbers, CURE Epilepsy, USA, Elisa Zanier, Mario Negri, Italy
• Panelists: Daniel Correa, MD, MS, Ramon Diaz-Arrastia, MD, PhD, Christopher Dulla, PhD, Pavel Klein, MD, Mary Jo Pugh, PhD, RN, Douglas Smith, MD